SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: William Whitehead Jr. who wrote (1464)9/20/1998 3:21:00 PM
From: Jonathan M. Traxler  Read Replies (1) | Respond to of 2173
 
Good article, but remember they haven't shown anything as far as tangible results, as well as the fact they might run out of money.

At $3.00 a share I'd rather just hold and hope. If it dies how much lower does it really go? Heck it's already in the "write off" category as far as my account thinks, might as well just hold longer.

-Jon



To: William Whitehead Jr. who wrote (1464)9/24/1998 9:29:00 PM
From: jbershad  Read Replies (1) | Respond to of 2173
 
All true. insiders and institutions brought.
If drug for diabetes II works everything in
place for a blast off.

The dosage given has big problems. Reason
for delays. Lets hope it clears up.

Jerry


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News